ValiRx Plc
("ValiRx" or the "Company")
Shareholder Requisition Notice
London, UK, 4 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has received a letter from a group of shareholders (the "Letter") who hold in excess of 5% of the issued share capital of the Company, requiring that the Company convene, as soon as reasonably practicable, a general meeting, at which resolutions will be proposed to remove George Morris and Satu Vainikka as directors of the Company.
The Letter is a requisition under section 303 of the Companies Act 2006.
The Company is mindful that, pursuant to section 304 of the Companies Act 2006, the Company must post a notice convening a general meeting within 21 days from the date on which the requisition notice was received, and this general meeting must be held on a date not more than 28 days after the date of the notice to shareholders convening the general meeting.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For more information, please contact:
ValiRx plc |
Tel: +44 (0) 20 3008 4416 www.valirx.com |
Kevin Alexander, Non-executive Director |
Tel: +44 (0) 20 3008 4416 |
Tarquin Edwards, Head of Communications. |
Tel: +44 (0) 7879 458 364 [email protected] |
|
|
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti |
Tel: +44 (0) 20 7213 0880 |
|
|
Allenby Capital Limited (Joint Broker) Jeremy Porter / Alex Brearley (Corporate Finance) Kelly Gardiner (Equity Sales) |
Tel: +44 (0) 20 3328 5656 |
|
|
ETX Capital Limited (Joint Broker) Thomas Smith |
Tel: +44 (0) 20 7392 1568 |
Novum Securities Limited (Joint Broker) Colin Rowbury |
Tel: +44 (0) 20 7399 9400 |
